DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
The generic ingredient in CONSENSI is amlodipine besylate; celecoxib. There are fifty drug master file entries for this compound. Additional details are available on the amlodipine besylate; celecoxib profile page.
Generic Entry Opportunity Date for 210045
Generic Entry Date for 210045*:
Constraining patent/regulatory exclusivity:
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET;ORAL||Strength||EQ 2.5MG BASE;200MG|
|Approval Date:||May 31, 2018||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||May 31, 2021|
|Regulatory Exclusivity Use:||NEW COMBINATION|
|Patent:||Start Trial||Patent Expiration:||Jun 14, 2038||Product Flag?||Y||Substance Flag?||Delist Request?|
|Patent:||Start Trial||Patent Expiration:||May 22, 2029||Product Flag?||Y||Substance Flag?||Delist Request?|
|Patented Use:||TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE|
Complete Access Available with Subscription